©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13343-13368
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13343
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13343
Table 4 Antigenic sources used in pancreatic cancer vaccine trials
| Peptide or protein vaccines | Mutant K-ras peptide |
| WT1 peptide | |
| CAP1-6D | |
| G17DT | |
| HLA-A*0201 restricted VEGF receptor-1 and -2 peptides | |
| HLA-A24 restricted survivin-2B80-88 peptide (AYACNTSTL) | |
| Autologous heat shock protein HSPPC-96 | |
| TELOVAC | |
| Whole cell vaccines or dendritic cell vaccines | α-Gal transferase transfected allogeneic tumor cells (including Algenpantucel-L) |
| GVAX | |
| MUC-1 pulsed autologous dendritic cells | |
| Viral or bacterial vaccines | PANVAC-VF-MUC-1, CEA, and TRICOM transfected virus |
| Mesothelin (CRS-207) transfected live-attenuated Listeria | |
| DNA vaccines | VXMO1 |
- Citation: Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20(37): 13343-13368
- URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13343.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13343